vs

Side-by-side financial comparison of Hess Midstream LP (HESM) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Hess Midstream LP is the larger business by last-quarter revenue ($404.2M vs $207.3M, roughly 2.0× Ultragenyx Pharmaceutical Inc.). Hess Midstream LP runs the higher net margin — 23.1% vs -62.0%, a 85.1% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 2.1%). Hess Midstream LP produced more free cash flow last quarter ($178.9M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 6.6%).

Hess Corporation is an American global independent energy company involved in the exploration and production of crude oil and natural gas. It was formed by the merger of Hess Oil and Chemical and Amerada Petroleum in 1968. Leon Hess was CEO from the early 1960s until 1995, after which his son John B Hess succeeded him as chairman and CEO. The company agreed to be acquired by rival oil company Chevron in October 2023, and the acquisition closed in July 2025.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

HESM vs RARE — Head-to-Head

Bigger by revenue
HESM
HESM
2.0× larger
HESM
$404.2M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+23.8% gap
RARE
25.9%
2.1%
HESM
Higher net margin
HESM
HESM
85.1% more per $
HESM
23.1%
-62.0%
RARE
More free cash flow
HESM
HESM
$279.7M more FCF
HESM
$178.9M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
6.6%
HESM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HESM
HESM
RARE
RARE
Revenue
$404.2M
$207.3M
Net Profit
$93.3M
$-128.6M
Gross Margin
Operating Margin
62.2%
-54.7%
Net Margin
23.1%
-62.0%
Revenue YoY
2.1%
25.9%
Net Profit YoY
32.5%
3.5%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HESM
HESM
RARE
RARE
Q4 25
$404.2M
$207.3M
Q3 25
$420.9M
$159.9M
Q2 25
$414.2M
$166.5M
Q1 25
$382.0M
$139.3M
Q4 24
$395.9M
$164.6M
Q3 24
$378.5M
$139.5M
Q2 24
$365.5M
$147.0M
Q1 24
$355.6M
$108.8M
Net Profit
HESM
HESM
RARE
RARE
Q4 25
$93.3M
$-128.6M
Q3 25
$97.7M
$-180.4M
Q2 25
$90.3M
$-115.0M
Q1 25
$71.6M
$-151.1M
Q4 24
$70.4M
$-133.2M
Q3 24
$58.6M
$-133.5M
Q2 24
$49.5M
$-131.6M
Q1 24
$44.6M
$-170.7M
Operating Margin
HESM
HESM
RARE
RARE
Q4 25
62.2%
-54.7%
Q3 25
61.5%
-106.9%
Q2 25
62.8%
-64.8%
Q1 25
62.1%
-102.6%
Q4 24
61.4%
-74.3%
Q3 24
61.2%
-94.6%
Q2 24
60.8%
-79.1%
Q1 24
62.4%
-151.9%
Net Margin
HESM
HESM
RARE
RARE
Q4 25
23.1%
-62.0%
Q3 25
23.2%
-112.8%
Q2 25
21.8%
-69.0%
Q1 25
18.7%
-108.5%
Q4 24
17.8%
-80.9%
Q3 24
15.5%
-95.7%
Q2 24
13.5%
-89.5%
Q1 24
12.5%
-156.8%
EPS (diluted)
HESM
HESM
RARE
RARE
Q4 25
$-1.28
Q3 25
$-1.81
Q2 25
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$-1.40
Q2 24
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HESM
HESM
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$1.9M
$421.0M
Total DebtLower is stronger
$3.8B
Stockholders' EquityBook value
$-80.0M
Total Assets
$4.4B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HESM
HESM
RARE
RARE
Q4 25
$1.9M
$421.0M
Q3 25
$5.5M
$202.5M
Q2 25
$4.5M
$176.3M
Q1 25
$6.1M
$127.1M
Q4 24
$4.3M
$174.0M
Q3 24
$10.3M
$150.6M
Q2 24
$99.6M
$480.7M
Q1 24
$4.2M
$112.3M
Total Debt
HESM
HESM
RARE
RARE
Q4 25
$3.8B
Q3 25
Q2 25
Q1 25
Q4 24
$3.5B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
HESM
HESM
RARE
RARE
Q4 25
$-80.0M
Q3 25
$9.2M
Q2 25
$151.3M
Q1 25
$144.2M
Q4 24
$255.0M
Q3 24
$346.8M
Q2 24
$432.4M
Q1 24
$140.3M
Total Assets
HESM
HESM
RARE
RARE
Q4 25
$4.4B
$1.5B
Q3 25
$4.4B
$1.2B
Q2 25
$4.4B
$1.3B
Q1 25
$4.3B
$1.3B
Q4 24
$4.2B
$1.5B
Q3 24
$4.1B
$1.5B
Q2 24
$4.1B
$1.6B
Q1 24
$3.9B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HESM
HESM
RARE
RARE
Operating Cash FlowLast quarter
$245.6M
$-99.8M
Free Cash FlowOCF − Capex
$178.9M
$-100.8M
FCF MarginFCF / Revenue
44.3%
-48.6%
Capex IntensityCapex / Revenue
16.5%
0.5%
Cash ConversionOCF / Net Profit
2.63×
TTM Free Cash FlowTrailing 4 quarters
$728.2M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HESM
HESM
RARE
RARE
Q4 25
$245.6M
$-99.8M
Q3 25
$258.9M
$-91.4M
Q2 25
$276.9M
$-108.3M
Q1 25
$202.4M
$-166.5M
Q4 24
$258.5M
$-79.3M
Q3 24
$224.9M
$-67.0M
Q2 24
$271.6M
$-77.0M
Q1 24
$185.3M
$-190.7M
Free Cash Flow
HESM
HESM
RARE
RARE
Q4 25
$178.9M
$-100.8M
Q3 25
$178.9M
$-92.7M
Q2 25
$213.5M
$-110.7M
Q1 25
$156.9M
$-167.8M
Q4 24
$163.4M
$-79.5M
Q3 24
$132.6M
$-68.6M
Q2 24
$207.7M
$-79.0M
Q1 24
$130.5M
$-193.9M
FCF Margin
HESM
HESM
RARE
RARE
Q4 25
44.3%
-48.6%
Q3 25
42.5%
-58.0%
Q2 25
51.5%
-66.5%
Q1 25
41.1%
-120.5%
Q4 24
41.3%
-48.3%
Q3 24
35.0%
-49.2%
Q2 24
56.8%
-53.7%
Q1 24
36.7%
-178.2%
Capex Intensity
HESM
HESM
RARE
RARE
Q4 25
16.5%
0.5%
Q3 25
19.0%
0.8%
Q2 25
15.3%
1.5%
Q1 25
11.9%
1.0%
Q4 24
24.0%
0.1%
Q3 24
24.4%
1.2%
Q2 24
17.5%
1.4%
Q1 24
15.4%
3.0%
Cash Conversion
HESM
HESM
RARE
RARE
Q4 25
2.63×
Q3 25
2.65×
Q2 25
3.07×
Q1 25
2.83×
Q4 24
3.67×
Q3 24
3.84×
Q2 24
5.49×
Q1 24
4.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HESM
HESM

Gathering$217.3M54%
Processing And Storage$154.7M38%
Terminaling And Export$32.2M8%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons